Uracil
Identification
- Name
- Uracil
- Accession Number
- DB03419
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Uracil (DB03419)
- Weight
- Average: 112.0868
Monoisotopic: 112.027277382 - Chemical Formula
- C4H4N2O2
- Synonyms
- Not Available
- External IDs
- BMS-205603-01
- NSC-3970
- SQ-6201
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism URibosomal small subunit pseudouridine synthase A Not Available Escherichia coli (strain K12) UUracil-DNA glycosylase Not Available HHV-1 UUracil-DNA glycosylase Not Available Escherichia coli O157:H7 UDihydropyrimidine dehydrogenase [NADP(+)] Not Available Humans UUridine-cytidine kinase-like 1 Not Available Humans UUracil-DNA glycosylase Not Available Thermus thermophilus UPyrimidine-nucleoside phosphorylase Not Available Geobacillus stearothermophilus - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
Pathway Category Carnosinuria, Carnosinemia Disease Pyrimidine Metabolism Metabolic MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy) Disease beta-Alanine Metabolism Metabolic beta-Ureidopropionase Deficiency Disease Dihydropyrimidinase Deficiency Disease UMP Synthase Deficiency (Orotic Aciduria) Disease GABA-Transaminase Deficiency Disease Ureidopropionase Deficiency Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcenocoumarol The risk or severity of bleeding can be increased when Uracil is combined with Acenocoumarol. Cimetidine The serum concentration of Uracil can be increased when it is combined with Cimetidine. Dicoumarol The risk or severity of bleeding can be increased when Uracil is combined with Dicoumarol. Fluindione The risk or severity of bleeding can be increased when Uracil is combined with Fluindione. Folic acid The risk or severity of adverse effects can be increased when Folic acid is combined with Uracil. Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Uracil. Gemcitabine The serum concentration of Uracil can be increased when it is combined with Gemcitabine. Gimeracil The serum concentration of Uracil can be increased when it is combined with Gimeracil. Leucovorin The risk or severity of adverse effects can be increased when Leucovorin is combined with Uracil. Levoleucovorin The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Uracil. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyrimidones
- Alternative Parents
- Hydropyrimidines / Vinylogous amides / Heteroaromatic compounds / Ureas / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides show 1 more
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine / Lactam / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound show 5 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- pyrimidone, pyrimidine nucleobase (CHEBI:17568) / pyrimidines (C00106) / a pyrimidine-related compound, a pyrimidine base (URACIL)
Chemical Identifiers
- UNII
- 56HH86ZVCT
- CAS number
- 66-22-8
- InChI Key
- ISAKRJDGNUQOIC-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)
- IUPAC Name
- 1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- O=C1NC=CC(=O)N1
References
- Synthesis Reference
Kurt Klemm, Wolfgang Schoetensack, Wolfgang Prusse, "Aryl-substituted piperazinyl-alkylamino-uracils, -uracil ethers and -uracil thioethers and method for their production." U.S. Patent US3957786, issued September, 1951.
US3957786- General References
- Not Available
- External Links
- PDB Entries
- 1bd4 / 1brw / 1emj / 1flz / 1gth / 1jls / 1ksk / 1ksl / 1oe5 / 1q3f … show 49 more
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 100 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 338 °C PhysProp water solubility 3600 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -1.07 HANSCH,C ET AL. (1995) logS -1.48 ADME Research, USCD Caco2 permeability -5.37 ADME Research, USCD pKa 9.45 MERCK INDEX (1996) - Predicted Properties
Property Value Source Water Solubility 26.5 mg/mL ALOGPS logP -1.2 ALOGPS logP -0.86 ChemAxon logS -0.63 ALOGPS pKa (Strongest Acidic) 9.77 ChemAxon pKa (Strongest Basic) -5.5 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 58.2 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 25.97 m3·mol-1 ChemAxon Polarizability 9.37 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9591 Blood Brain Barrier + 0.9907 Caco-2 permeable - 0.8957 P-glycoprotein substrate Non-substrate 0.785 P-glycoprotein inhibitor I Non-inhibitor 0.9543 P-glycoprotein inhibitor II Non-inhibitor 0.9968 Renal organic cation transporter Non-inhibitor 0.9073 CYP450 2C9 substrate Non-substrate 0.7561 CYP450 2D6 substrate Non-substrate 0.8331 CYP450 3A4 substrate Non-substrate 0.793 CYP450 1A2 substrate Non-inhibitor 0.7271 CYP450 2C9 inhibitor Non-inhibitor 0.9713 CYP450 2D6 inhibitor Non-inhibitor 0.9719 CYP450 2C19 inhibitor Non-inhibitor 0.981 CYP450 3A4 inhibitor Non-inhibitor 0.9707 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.993 Ames test Non AMES toxic 0.9178 Carcinogenicity Non-carcinogens 0.9471 Biodegradation Ready biodegradable 0.7648 Rat acute toxicity 1.2228 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9614 hERG inhibition (predictor II) Non-inhibitor 0.968
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Rna binding
- Specific Function
- Responsible for synthesis of pseudouridine from uracil-516 in 16S ribosomal RNA.
- Gene Name
- rsuA
- Uniprot ID
- P0AA43
- Uniprot Name
- Ribosomal small subunit pseudouridine synthase A
- Molecular Weight
- 25865.12 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- HHV-1
- Pharmacological action
- Unknown
- General Function
- Uracil dna n-glycosylase activity
- Specific Function
- Excises uracil residues from the DNA which can arise as a result of misincorporation of dUMP residues by DNA polymerase or deamination of cytosine. Therefore may reduce deleterious uracil incorpora...
- Gene Name
- Not Available
- Uniprot ID
- P10186
- Uniprot Name
- Uracil-DNA glycosylase
- Molecular Weight
- 36327.865 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Escherichia coli O157:H7
- Pharmacological action
- Unknown
- General Function
- Uracil dna n-glycosylase activity
- Specific Function
- Excises uracil residues from the DNA which can arise as a result of misincorporation of dUMP residues by DNA polymerase or due to deamination of cytosine.
- Gene Name
- ung
- Uniprot ID
- Q8X444
- Uniprot Name
- Uracil-DNA glycosylase
- Molecular Weight
- 25662.02 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein homodimerization activity
- Specific Function
- Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
- Gene Name
- DPYD
- Uniprot ID
- Q12882
- Uniprot Name
- Dihydropyrimidine dehydrogenase [NADP(+)]
- Molecular Weight
- 111400.32 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Uridine kinase activity
- Specific Function
- May contribute to UTP accumulation needed for blast transformation and proliferation.
- Gene Name
- UCKL1
- Uniprot ID
- Q9NWZ5
- Uniprot Name
- Uridine-cytidine kinase-like 1
- Molecular Weight
- 61140.395 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Thermus thermophilus
- Pharmacological action
- Unknown
- General Function
- Metal ion binding
- Specific Function
- Not Available
- Gene Name
- udg
- Uniprot ID
- Q5SKC5
- Uniprot Name
- Uracil-DNA glycosylase
- Molecular Weight
- 22965.68 Da
- Kind
- Protein
- Organism
- Geobacillus stearothermophilus
- Pharmacological action
- Unknown
- General Function
- Pyrimidine-nucleoside phosphorylase activity
- Specific Function
- Catalyzes phosphorolysis of the pyrimidine nucleosides uridine, thymidine and 2'-deoxyuridine with the formation of the corresponding pyrimidine base and ribose-1-phosphate.
- Gene Name
- pdp
- Uniprot ID
- P77836
- Uniprot Name
- Pyrimidine-nucleoside phosphorylase
- Molecular Weight
- 46331.92 Da
Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/linkouts/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/linkouts/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/linkouts/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/linkouts/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/linkouts/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/linkouts/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/linkouts/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/linkouts/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/linkouts/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/linkouts/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/linkouts/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/linkouts/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/linkouts/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/linkouts/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/linkouts/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/linkouts/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/linkouts/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/linkouts/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/linkouts/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/linkouts/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates